Back to today’s briefing

Story perspectives

ASCO Data: GLP-1 Users Show Lower Breast Cancer, Better Survival

6/5/2026

45 6

Summary

Story summary

Three GLP-1 studies were presented at the 2026 ASCO meeting in Chicago.
In 94,827 women, breast cancer occurred in 1.65% of GLP-1 users versus 2.6% of non-users.
In 604 GLP-1 users and controls, median survival was 67.9 months versus 49 months, a 30% lower death risk.
Cleveland Clinic analysis of obesity-related cancers showed lower progression in six cancers, significant in four, with all studies observational and causality unproven.

1 of 1

Story summary

Three GLP-1 studies were presented at the 2026 ASCO meeting in Chicago.
In 94,827 women, breast cancer occurred in 1.65% of GLP-1 users versus 2.6% of non-users.
In 604 GLP-1 users and controls, median survival was 67.9 months versus 49 months, a 30% lower death risk.
Cleveland Clinic analysis of obesity-related cancers showed lower progression in six cancers, significant in four, with all studies observational and causality unproven.